BioNTech

Leader

German mRNA pioneer behind COVID-19 vaccine with Pfizer; pivoting to mRNA cancer immunotherapies and oncology pipeline across 20+ clinical programs.

Company Overview

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.

Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Market Leader

BioNTech is recognized as a market leader in the Life Sciences & BioTech sector, demonstrating strong industry presence and customer trust.

Frequently Asked Questions

Not So Random Others

a2z Radiology AI

Enterprise AI
Ai PoweredB2bEnterpriseHealthtechSaasStartup

a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea

Adept AI

AI Infra
Ai PoweredAutomationB2bEnterpriseInfrastructurePlatformStartupSaas

Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec

Honda

Automotive
Asia PacificB2cGlobalHardwareManufacturingPublicTransportation

Honda Motor Co., Ltd. is a Japanese multinational mobility conglomerate founded in 1948 by Soichiro Honda and Takeo Fujisawa in Hamamatsu, Japan. Starting as a motorcycle manufacturer, Honda expanded

Hyundai

Automotive
Asia PacificB2cEvGlobalHardwareManufacturingPublicTransportation

Hyundai Motor Company was founded in 1967 in Seoul, South Korea, by Chung Ju-yung and has grown into one of the world's largest automotive manufacturers, ranking third globally by vehicle sales. From

Duckie

Infrastructure
Ai PoweredAutomationB2bInfrastructurePlatformCloud NativeSaas

Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit

Plenty

AgTech & Precision Agriculture Technology
AgricultureAi PoweredHardwareIotPlatformSaasScaleupStartupB2b

Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r

Compare BioNTech with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For BioNTech

Claim This Profile

Are you from BioNTech? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim BioNTech Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention BioNTech vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →